In Brief: Schering-Plough's Vancenase AQ
Executive Summary
Schering-Plough's Vancenase AQ: Switch to OTC status for Schering's beclomethasone dipropionate and Fisons' Nasalcrom (cromolyn sodium) nasal sprays (to be marketed by McNeil) will be considered at a joint meeting of FDA's Nonprescription Drugs and Pulmonary-Allergy Drugs Advisory Committees on Oct. 11. Both sprays would be indicated for the OTC treatment of seasonal allergic rhinitis at the current Rx dosage.... Chiral ibuprofen: On Oct. 10, FDA's Nonprescription Drugs and Arthritis Advisory Committees will consider an application for dexibuprofen to be marketed by Bayer. The application apparently is seeking approval straight to OTC status...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth